Pharvaris Announces Pricing of Upsized Initial Public Offering
February 04, 2021 20:08 ET | Source: Pharvaris N.V. Pharvaris N.V. CH Leiden, NETHERLANDS
ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwritin
NOTES Aquila European Renewables Income Fund plc ( AERIF or the Company ) is a London-listed renewable energy infrastructure investment company with the aim to provide investors with an attractive long-term, income-based return in EUR through a diversified portfolio of hydropower, wind and solar PV investments across continental Europe and Ireland. Through the diversification of generation technologies, the seasonal production patterns of these asset types complement each other to balance the cash flow, while the geographic diversification serves to reduce exposure to one single energy market. AERIF is targeting a minimum of 4.0 cents per ordinary share in relation to the financial year ending 31 December 2020 and 5.0 cents per ordinary share in respect of subsequent financial years, with the aim of increasing this dividend progressively over the medium term.
CureVac s Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This press release contains statements that constitute forward looking statements as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that
Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares
February 2, 2021 GMT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 2, 2021 / CureVac N.V. (Nasdaq:CVAC) (“CureVac” or the “Company”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as passive book-running managers for the offering.
Solar developer NextEnergy Renewables (NREN) is to launch an initial public offering and will seek admission to the London Stock Exchange.
The company wants to raise up to £300m through the share placement that would get underway this month and wrap up in March.
NREN will be managed by NextEnergy Capital IM Limited, a global specialist investment manager in the renewable energy sector and part of NextEnergy Group.
NREN is a “differentiated renewables investment company” that aims to capture the “most attractive” private renewables and energy transition infrastructure investment opportunities globally.
The company said its ambition is to increase the global renewable energy supply through established clean energies available.